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summary
The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a 
multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, 
or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain 
symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience 
moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic 
widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM 
is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) 
inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA 
alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall 
quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such 
as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs. 
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n	 INTRODUCTION
Spondyloarthritis (SpA) refers to a fam-ily of diseases with a number of com-
mon clinical features (1). The most dis-
tinguishing are axial joint inflammation, 
asymmetric oligoarthritis, dactylitis and 
enthesitis, but others include genital and 
skin lesions, eye and bowel involvement, 
an association with current or previous in-
fection, and a close correlation with human 
leukocyte antigen (HLA) B27 (2, 3). 
The pain associated with SpA can be in-
tense, persistent and disabling (4, 5). It 
frequently has a multifactorial, simultane-
ously central and peripheral origin (6), and 
may be due to currently active inflamma-
tion, or joint damage and tissue destruc-
tion arising from a previous inflammatory 
condition (7). Inflammatory pain symp-
toms can be reduced by non-steroidal anti-
inflammatory drugs (NSAIDs), but many 
patients continue to experience moderate 
pain (8, 9) due to alterations in the mecha-
nisms that regulate central pain, as in the 
case of the chronic widespread pain (CWP) 
that characterises fibromyalgia (FM) (10). 
The many complex mechanisms giving 
rise to CWP include temporal summation 
(wind-up), long-term potentiation (LTP), 
heterosynaptic potentiation, dysfunctional 
descending pain inhibition, and activation 
of the descending facilitatory pathway (11). 
Experimental studies of sensitivity to pain 
have shown that the pressure eliciting pain 
(also known as the pressure pain threshold 
or PPT) is lower in patients with rheuma-
toid arthritis (RA) than in healthy controls 
(6). The fact that this true at articular and 
non-articular sites suggests that the wide-
spread pain associated with RA is mediated 
by changes in the mechanisms regulating 
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central pain, such as central sensitisation 
and a lack of conditioned pain modula-
tion. Incel et al. studied 17 Ankylosing 
Spondylitis (AS) patients, 20 RA patients, 
and 21 healthy volunteers, and found that 
the PPTs of the RA patients (but not those 
with AS) were significantly lower than the 
PPTs of healthy volunteers (12). However, 
other studies have shown that widespread 
pain conditions such as FM significantly 
increase AS disease activity. The growing 
evidence that there is an association be-
tween FM and SpA increases the need to 
distinguish their clinical features because 
the evaluation of SpA can be complicated 
by the presence of FM (13-16). The main 
cause of diagnostic confusion relating to 
the 1990 American College of Rheumatol-
ogy (ACR) criteria (17) is the overlap of 
enthesitis in SpA with the tender points 
(TPs) of FM. TP counts were therefore 
replaced by patient self-assessment in the 
2010 ACR diagnostic criteria for FM (18), 
but this has has not necessarily made them 
any less confusing (19). The two conditions 
have many similarities. SpA is diagnosed 
on the basis of the presence of inflammato-
ry chronic back pain and morning stiffness 
(20, 21), but these are often encountered 
in FM patients. Furthermore, the typical 
characteristics of FM (fatigue, depres-
sion, anxiety and sleep disturbances) (22) 
are also significant aspects of AS, and are 
closely associated with pain, particularly 
in women (21). Such similarities not only 
lead to diagnostic problems, but may also 
make it more difficult to interpret treatment 
failure or disease relapse (23). Consequent-
ly, it has been suggested that SpA and FM 
can best be differentiated by means of the 
power Doppler ultrasound (PDUS) inves-
tigation of enthesitis (24), although this is 
not universally available in everyday clini-
cal practice (25, 26).
n	 THE IMPACT OF CWP  
 ON DISEASE ACTIVITY  
 INDICES
Disease activity indices are often used in 
patients with SpA (27, 28), and the good 
correlation between the presence of CWP 
or FM and the self-reported indices of AS 
(including the Bath Ankylosing Spondyli-
tis Disease Activity Index, BASDAI) (29) 
suggests that the CWP frequently observed 
in women with inflammatory rheumatic 
diseases may also be frequent in women 
with axial SpA. This may cause diagnostic 
delays, and could provide a further expla-
nation for the finding that, at any given lev-
el of radiographic damage, women’s self-
reported functional limitations are worse 
than those of men. As women with primary 
FM have much higher BASDAI scores than 
women with AS (23), BASDAI may not be 
a good means of assessing inflammatory 
disease activity in SpA patients. 
Patients with concomitant AS and FM 
are more functionally impaired, and have 
higher BASDAI and Ankylosing Spondy-
litis Functional Index (BASFI) scores than 
those of patients with either disease alone 
(30). The prevalence of FM in one study 
of 71 patients with AS was 15% (45.5% 
males and 54.5% females), and these pa-
tients all had significantly higher BASDAI, 
BASFI and Ankylosing spondylitis quality 
of life (ASQoL) scores (31). Furthermore, 
a cross-sectional Spanish study of 462 
patients with definite AS found that their 
BASDAI, BASFI and total Bath AS Radi-
ology Index (BASRI) scores were all great-
ly affected by the presence of FM, which 
distorted the measures of disease activity 
and functional damage (32). 
Another cross-sectional study has found 
that FM is also frequent in axial SpA, and 
once again more prevalent in female pa-
tients (33). Having can worsen the symp-
toms of disease activity, affect function, 
and compromise the quality of life: as the 
Ankylosing Spondylitis Disease Activity 
Score (ASDAS) includes markers of in-
flammation markers it may be more useful 
than BASDAI in clinical practice.
One study of 547 patients in the Scot-
land and Ireland Registry for Ankyolsing 
Spondylitis (SIRAS) (34) used four-view 
body manikins to obtain information con-
cerning CWP not only on the basis of the 
1990 ACR criteria for FM (ACR-CWP: i.e. 
chronic pain for >3 months in two contra-
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lateral body quadrants, plus axial pain), but 
also on the basis of an alternative defini-
tion (aCWP) that required chronic pain 
in two contralateral body quadrants, but 
excluded pain in the axial skeleton and/
or buttocks because it was felt that spinal 
disease would greatly affect the reporting 
and complicate the interpretation of the re-
sults.  It was found that the age- and gen-
der- adjusted prevalence of aCWP in AS 
was almost three times higher than in the 
general population, and was related to both 
individual and clinical factors (34).
n	 CWP AND PSORIATIC  
 ARTHRITIS
Psoriatic arthritis (PsA) is a chronic inflam-
matory arthropathy of unknown etiology 
whose various manifestations include mo-
no-oligoarthritis (an erosive polyarthritis 
that indistinguishable from RA) and spon-
dyloarthropathy with axial involvement or 
enthesitis, and affect up to one-third of pso-
riatic patients (35). Although the real prev-
alence of CWP in PsA patients is unclear, 
one study found tenderness in ten or more 
fibrotic sites in 24% of patients with PsA 
and 57% of RA patients (36). If there are no 
objective signs of entheseal inflammation, 
it can be difficult to distinguish enthesitic 
and CWP clinically, because the symptoms 
and signs may be aspecific. However, uni-
variate analysis of a cross-sectional study 
of 266 patients with PsA and 120 with FM 
(37) showed that the latter had higher mean 
TPs and enthesitis scores, more somatic 
symptoms, and responded less to NSAIDs, 
and multivariate analysis showed that the 
presence of ≥6 FM-associated symptoms 
and ≥8 TPs was the best predictor of FM. 
The authors concluded that PsA and FM 
have some common clinical features, but 
that the number of FM-associated symp-
toms and the number of TPs were the most 
useful variables distinguishing FM.
As in the case of RA, the inflammation 
affecting different tissues in PsA patients 
can be detected and characterised early by 
means of ultrasonography, which is useful 
for the differential diagnosis.
n	 TREATMENT OF PATIENTS  
 WITH SPA AND  
 CONCOMITANT CWP
Although challenging, it is important to 
identify CWP in SpA patients because it 
can have a considerable impact on their 
health-related quality of life, and is asso-
ciated with high rates of use of healthcare 
resources (38-40). The difficulties in ev-
eryday living activities reported by patients 
with CWP or FM are as severe as those re-
ported by patients with RA (41), and more 
severe than those reported by patients with 
osteoarthritis or other painful conditions 
(42, 43). The general level of well-being of 
FM patients referred to a specialist is lower 
than that of patients with AS, and they are 
also more expensive to treat (44). Howev-
er, the direct costs of treating concomitant 
SpA (which is currently treated with costly 
tumour necrosis factor (TNF) inhibitors) 
and CWP or FM are higher than those of 
treating FM or SpA alone (45). 
It is particularly important to recognise the 
presence of concomitant CWP in patients 
with chronic structural diseases in order 
to ensure their optimal management. Anti-
TNF drugs are ineffective in patients com-
plaining of pain even when inflammation is 
effectively controlled, and this can lead to 
unnecessary changes in treatment or dose 
escalations. 
Treating CWP in SpA patients is particu-
larly challenging because little is known 
about its etiology and the patients respond 
poorly to conventional treatments: for ex-
ample, NSAIDs alone have no effect on 
CWP caused by central sensitisation, and 
are probably unlikely to be effective in 
SpA patients (8, 9).
Controlled studies have shown that tricy-
clic antidepressants (e.g. amitriptyline), 
selective serotonin reuptake inhibitors (e.g. 
fluoxetine), and dual serotonin and norepi-
nephrine inhibitors (e.g. venlafaxine, mil-
nacipram and duloxetine) can relieve pain 
and improve the quality of life patients 
with FM (46, 47). 
The most widely accepted and beneficial 
forms of non-pharmacological therapy 
seem to be physical exercise and multi-
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modal cognitive behavioural therapy (46, 
47). However, as no single pain treatment 
is ideal, it is recommended to adopt an ap-
proach based on combined treatments. 
n	 CONCLUSIONS
Chronic widespread pain in SpA or PsA 
does not increase overall mortality but neg-
atively affects the patients’ quality of life, 
and its presence should be recognised by 
rheumatologists. Mechanism-based pain 
management should consider its simulta-
neous peripheral and central origin, includ-
ing the effects of inputs from the brain and 
the descending inhibitory pathways, and 
optimal therapy should take into account 
symptoms such as fatigue, mood and dis-
turbed sleep.
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